CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Choosing between a Sep Ira and a Simple Ira can be challenging. Discover the key factors to consider for your retirement savings strategy.
15,615 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Investor confidence is up—what’s making headlines? This article breaks down the forces behind a sunnier mood, what it...
A leading bank projects XRP could reach $28 by 2030, even as Ripple pushes a new stablecoin. The forecast highlights ...
Federal prosecutors dismantle a sprawling fraud machine that used mass texting, scripted pitches, and fake crypto pla...
A near-10-year divorce can erase months of divorced-spouse Social Security benefits. The calendar, not sentiment, det...
Nexa Lending’s Loren Riddick outlines how policy reform could reshape the HECM program, addressing reverse-to-reverse...
SpaceX sits on a colossal cash hoard, but does $100 billion guarantee long-term growth? This guide breaks down what t...
Prediction-market trading on Iran’s leadership surged as tensions flared, but unverified rumors triggered rapid price...
With Kevin Warsh at the helm, the Fed signals a cautious but hawkish tilt. Borrowers should prepare for higher rates ...
Energy markets moved on geopolitical headlines, lifting ConocoPhillips stock in intraday trading. This article explai...
As AI workloads push data-center networks to the limit, seven firms are rising as the backbone of AI connectivity. Th...
Retirees are dialing in on steady monthly income. Here are five dependable dividend pay stocks that aim to deliver re...